CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
The emergence of CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, has revolutionized the treatment landscape for hormone receptor-positive breast cancer. These agents have demonstrated significant clinical benefits in terms of both progression-free survival and overall survival....
Main Authors: | Jin Sun Lee, Hannah Hackbart, Xiaojiang Cui, Yuan Yuan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/14/11791 |
Similar Items
-
Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
by: Jin Sun Lee, et al.
Published: (2022-06-01) -
CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
by: ZHANG Baihong, et al.
Published: (2019-01-01) -
MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
by: Neil Portman, et al.
Published: (2021-11-01) -
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
by: Fiona H. Zhou, et al.
Published: (2023-03-01) -
CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
by: Debora de Melo Gagliato, et al.
Published: (2020-09-01)